<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="received: 2007-11-27 rev-recd: 2008-3-7 accepted: 2008-3-10 (C) , Abstract Pediatric" exact="migraine" post="is a disabling condition, which can cause a significant"/>
 <result pre="efficacy and tolerability of topiramate in the prophylactic treatment of" exact="migraine" post="in children and adolescents. A total of five papers"/>
 <result pre="we strongly recommend to assess the disability caused by the" exact="migraine" post="episodes before deciding to initiate a prophylactic treatment. Nevertheless,"/>
 <result pre="very low. Keywords Migraine Headache Children Pediatric Topiramate Introduction Pediatric" exact="migraine" post="is a disabling condition, which can cause a significant"/>
 <result pre="10% [ 1]. About 3–5% of school-aged children suffer from" exact="migraine" post="and this proportion gradually increases to 20% through adolescence."/>
 <result pre="which remains through adulthood [ 2, 3]. Management of pediatric" exact="migraine" post="includes lifestyle changes (in order to avoid foods, habits"/>
 <result pre="avoid foods, habits or enviromental factors that may trigger a" exact="migraine" post="attack), the use of abortive medications and preventive measures,"/>
 <result pre="social functioning (including sports) [ 7, 8]. The assessment of" exact="migraine" post="disability is particularly important in children to correctly evaluate"/>
 <result pre="and in many other countries for the preventive treatment of" exact="migraine" post="in adults and for the treatment of partial-onset seizures"/>
 <result pre="efficacy and tolerability of topiramate in the prophylactic treatment of" exact="migraine" post="in children and adolescents. Materials and methods We searched"/>
 <result pre="had been enrolled in three pivotal RCTs of topiramate for" exact="migraine" post="prophylaxis in adults and two open studies. In a"/>
 <result pre="a day) for 12 weeks. Participants had a diagnosis of" exact="migraine" post="without aura (according to 2004 International Headache Society criteria)"/>
 <result pre="Children with comorbid medical associations or who were already on" exact="migraine" post="prophylaxis were excluded. Primary outcome measures were the reduction"/>
 <result pre="prophylaxis were excluded. Primary outcome measures were the reduction in" exact="migraine" post="frequency and severity; secondary outcome measures included number of"/>
 <result pre="The percentage of topiramate-treated subjects showing &amp;gt;50% reduction in monthly" exact="migraine" post="days during the double-blind phase was 95.2% as opposed"/>
 <result pre="This seems a well-performed trial in which the mean monthly" exact="migraine" post="frequency reduction is clearly evident in the topiramate-treated group."/>
 <result pre="household or social activities to a lesser extent than the" exact="migraine" post="episodes. The other Class I, randomized, double-blind, placebo-controlled trial"/>
 <result pre="12 weeks) or placebo. Eligible criteria were the children with" exact="migraine" post="with or without aura, weighing more than 20 kg,"/>
 <result pre="without aura, weighing more than 20 kg, who experienced 3–10" exact="migraine" post="days/month for the 3 months prior to the screening"/>
 <result pre="migraine, analgesic overuse and previous failure of ≥2 adequately dosed" exact="migraine" post="preventive medications. One hundred and fifty-seven subjects were included"/>
 <result pre="treated with topiramate. Primary outcome measure was the reduction of" exact="migraine" post="days per month in each treatment group of the"/>
 <result pre="baseline phase, there was a reduction of 2.6 ± 2.6" exact="migraine" post="days per month in the topiramate group compared with"/>
 <result pre="group compared with a mean reduction of 2.0 ± 3.1" exact="migraine" post="days per month in the placebo group ( P"/>
 <result pre="= 0.061). In the per-protocol population, the reduction in monthly" exact="migraine" post="days (2.8 ± 2.4 as opposed to 2.2 ±"/>
 <result pre="last 28 days of treatment, the mean number of monthly" exact="migraine" post="was reduced by 3.1 ± 2.6, as opposed to"/>
 <result pre="32% of patients experienced a ≥75% reduction in mean monthly" exact="migraine" post="days compared with a 14% reduction in the placebo"/>
 <result pre="topiramate-treated patients and included infection ( n = 2), severe" exact="migraine" post="( n = 1) and suicidal ideation ( n"/>
 <result pre="( n = 1). In this study, the mean monthly" exact="migraine" post="frequency reduction seems less evident when compared to the"/>
 <result pre="when compared to the previous study [ 10], probably because" exact="migraine" post="frequency at baseline was lower (range 2–9 in the"/>
 <result pre="2–9 in the ITT topiramate population) and children with chronic" exact="migraine" post="were excluded. An important aspect is that the reduction"/>
 <result pre="had been enrolled in three pivotal trials of topiramate for" exact="migraine" post="prophylaxis in adults. Patients were to have had between"/>
 <result pre="adults. Patients were to have had between 3 and 12" exact="migraine" post="attacks, and no more than 14 headache days per"/>
 <result pre="weeks. When compared to baseline, there was a mean monthly" exact="migraine" post="frequency reduction of 46, 63 and 65%, respectively, as"/>
 <result pre="all studies. Furthermore, the degree of disability caused by the" exact="migraine" post="episodes, which is essential in the decision to initiate"/>
 <result pre="was not assessed in all studies. Discussion Management of pediatric" exact="migraine" post="can be tricky, seeing as no pharmacological treatment is"/>
 <result pre="is formally approved or indicated in the prophylactic treatment of" exact="migraine" post="in children and adolescents. A recent review of the"/>
 <result pre="A recent review of the pharmacological treatment options in pediatric" exact="migraine" post="[ 16] found only flunarizine, which is not available"/>
 <result pre="placebo-controlled trials evaluating topiramate in the preventive treatment of pediatric" exact="migraine" post="have been carried out [ 10, 12]. Taken together,"/>
 <result pre="dosages, which seem to be effective in the treatment of" exact="migraine" post="in children and adolescents (2–3 mg/kg/day) are much lower"/>
 <result pre="much lower than those indicated for the adjunctive treatment of" exact="epilepsy" post="(5–9 mg/kg/day) in children as young as 2 years."/>
 <result pre="and should take the degree of disability caused by the" exact="migraine" post="episodes into account. An important aspect, which emerged from"/>
 <result pre="studies, is a significant decrease in school absenteeism due to" exact="migraine" post="[ 10] and a reduction in the disability caused"/>
 <result pre="[ 10] and a reduction in the disability caused by" exact="migraine" post="(as assessed by PedMIDAS), leading to an improvement in"/>
 <result pre="References 1. Abu-Arefeh I Russell G Prevalence of headache and" exact="migraine" post="in schoolchildren Br Med J 1994 309 765 769"/>
 <result pre="Silberstein SD Stewart WF An update on the epidemiology of" exact="migraine" post="Headache 1994 34 319 328 10.1111/j.1526-4610.1994.hed3406319.x 7928310 3. Stewart"/>
 <result pre="Natta M Ziegler D Age and sex-specific incidence rates of" exact="migraine" post="with and without aura Am J Epidemiol 1991 134"/>
 <result pre="RB Kolodner K Liberman J Sawyer J Reliability of the" exact="migraine" post="disability assessment score in a population-based sample of headache"/>
 <result pre="of the Child Neurology Society Practice parameter: pharmacological treatment of" exact="migraine" post="headache in children and adolescents: report of the American"/>
 <result pre="Linder SL Jordan DM Fisher AC Hulihan J Topiramate for" exact="migraine" post="prevention in children: a randomized, double-blind, placebo-controlled trial Headache"/>
 <result pre="Wang S Yuen E Battisti W Nye JS Topiramate for" exact="migraine" post="prevention in adolescents: a pooled analysis of efficacy and"/>
 <result pre="Casas C Herranz JL Topiramate in the prophylactic treatment of" exact="migraine" post="in children J Child Neurol 2005 20 251 253"/>
</results>
